Personalized Cancer Vaccine Shows Promise in Swiss Trials

A new personalized cancer vaccine is showing encouraging results in early trials, offering a potential breakthrough for patients with advanced cancers that have become resistant to traditional treatments. The development of innovative immunotherapies is a critical area of cancer research, aiming to harness the body’s own immune system to fight the disease.

Researchers at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have successfully developed a therapeutic vaccine tailored to individual patients’ tumors. Their work has earned them the 2026 Pfizer Biomedical Research Award, to be presented this Thursday.

The technology involves taking a sample of the patient’s tumor, deactivating the cancer cells while preserving their unique characteristics, and then re-injecting this material to “train” the immune system to recognize and attack the cancer. Simultaneously, a device implanted under the skin releases a substance that stimulates and strengthens the immune response, even in patients weakened by prior treatments like chemotherapy.

The result of fifteen years of research, the vaccine was tested in humans for the first time with positive outcomes. Thirty-four individuals with advanced solid tumors, which had not responded to any other therapies, participated in the trial. Over half of the participants demonstrated clinical benefit, ranging from disease control to prolonged survival. No significant side effects were observed. “This therapy is minimally invasive and very well tolerated, which is essential considering the often harsh side effects of standard treatments,” explained Dr. Eugenio Fernandez, Deputy Head of the Oncology Department at Geneva University Hospitals.

While these results are not yet conclusive proof of widespread effectiveness, they pave the way for a new generation of cancer immunotherapies. “There is still much work to be done! We now need to test this technology on larger groups of patients, at earlier stages of the disease, and combine it with existing treatments,” said one of the researchers. “But we are starting from a solid foundation.”